Literature DB >> 11015380

Pneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones.

B Beall1, G Gherardi, R R Facklam, S K Hollingshead.   

Abstract

In a recent genotypic survey of beta-lactam-resistant pneumococci recovered in different areas of United States during 1997, eight clonal types that each represented 3 to 40 isolates accounted for 134 of 144 isolates (G. Gherardi, C. Whitney, R. Facklam, and B. Beall, J. Infect. Dis. 181:216-229, 2000). We determined the degree of pspA gene diversity among these 134 isolates and for 11 previously characterized internationally disseminated multiresistant strains. Thirty-four different pspA restriction profiles were determined for an amplicon encompassing the variable portion of the structural gene that encodes the surface-exposed domain of PspA and a variable-length proline-rich putative cell wall-associated domain. These restriction profiles closely correlated with those of 33 different pspA sequence types of an approximately 230-residue region corresponding to residues 182 to 410 of the strain Rx1 PspA. These residues encompass a 100-residue clade-defining region known to contain cross-protective epitopes for which 17 sequence types were found. Distinct, conserved pspA sequence types were found for the majority of strains within seven of the eight U.S. clonal types assessed, while one pulsed-field gel electrophoresis type was represented by isolates of three distinct PspA clades. Sequence typing of pspA provides an added level of specificity in the subtyping of isolates and is a necessary first step in determining the components needed in a PspA vaccine which could elicit effective cross-protective coverage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015380      PMCID: PMC87453     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Genetic relationships of penicillin-susceptible and -resistant Streptococcus pneumoniae strains isolated on different continents.

Authors:  C Sibold; J Wang; J Henrichsen; R Hakenbeck
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

2.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.

Authors:  S K Hollingshead; R Becker; D E Briles
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis.

Authors:  J Yother; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

5.  Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae.

Authors:  T Kelly; J P Dillard; J Yother
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

6.  Pneumococcal polysaccharide immunization in infants and children.

Authors:  M J Cowan; A J Ammann; D W Wara; V M Howie; L Schultz; N Doyle; M Kaplan
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

7.  Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae.

Authors:  T J Coffey; C G Dowson; M Daniels; J Zhou; C Martin; B G Spratt; J M Musser
Journal:  Mol Microbiol       Date:  1991-09       Impact factor: 3.501

8.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

9.  PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.

Authors:  L S McDaniel; J S Sheffield; P Delucchi; D E Briles
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260.

Authors:  L S McDaniel; B A Ralph; D O McDaniel; D E Briles
Journal:  Microb Pathog       Date:  1994-11       Impact factor: 3.738

View more
  17 in total

1.  Phenotypic and genotypic characterization of two penicillin-susceptible serotype 6B Streptococcus pneumoniae clones circulating in Italy.

Authors:  Giovanni Gherardi; Maria Del Grosso; Anna Scotto D'Abusco; Fabio D'Ambrosio; Giordano Dicuonzo; Annalisa Pantosti
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  Genetic diversity of PspA types among nasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil.

Authors:  Fabiana Cristina Pimenta; Fátima Ribeiro-Dias; Maria Cristina C Brandileone; Eliane N Miyaji; Luciana C C Leite; Ana Lúcia S Sgambatti de Andrade
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Diversity of pneumococcal surface protein A (PspA) and relation to sequence typing in Streptococcus pneumoniae causing invasive disease in Chinese children.

Authors:  J Qian; K Yao; L Xue; G Xie; Y Zheng; C Wang; Y Shang; H Wang; L Wan; L Liu; C Li; W Ji; Y Wang; P Xu; S Yu; Y-W Tang; Y Yang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-04       Impact factor: 3.267

4.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

5.  Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4.

Authors:  Krzysztof Trzcinski; Claudette M Thompson; Marc Lipsitch
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

6.  Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Authors:  M Darrieux; E N Miyaji; D M Ferreira; L M Lopes; A P Y Lopes; B Ren; D E Briles; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

7.  Pneumococcal surface protein A family types of Streptococcus pneumoniae from community-acquired pneumonia patients in Japan.

Authors:  Y Ito; M Osawa; R Isozumi; S Imai; I Ito; T Hirai; T Ishida; S Ichiyama; M Mishima
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10       Impact factor: 3.267

8.  Genotypes of invasive pneumococcal isolates recently recovered from Italian patients.

Authors:  Giordano Dicuonzo; Giovanni Gherardi; Robert E Gertz; Fabio D'Ambrosio; Antonio Goglio; Giulia Lorino; Simona Recchia; Annalisa Pantosti; Bernard Beall
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

9.  PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.

Authors:  Wei Xin; Yuhua Li; Hua Mo; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

10.  Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.

Authors:  Il Gyu Kong; Ayuko Sato; Yoshikazu Yuki; Tomonori Nochi; Haruko Takahashi; Shinichi Sawada; Mio Mejima; Shiho Kurokawa; Kazunari Okada; Shintaro Sato; David E Briles; Jun Kunisawa; Yusuke Inoue; Masafumi Yamamoto; Kazunari Akiyoshi; Hiroshi Kiyono
Journal:  Infect Immun       Date:  2013-03-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.